Guselkumab (Tremfya) Gets CHMP Backing for Plaque Psoriasis Guselkumab (Tremfya) Gets CHMP Backing for Plaque Psoriasis

The drug selectively targets IL-23, a key driver of the immune inflammatory response in patients with psoriasis.International Approvals

Source: Medscape Today Headlines - September 15, 2017 Category: Consumer Health News Tags: Dermatology News Alert Source Type: news